Shots:

• Synaffix to receive $4.5M up front on a targeted basis with the total deal value of ~$415M & is eligible to receive option exercise, development, regulatory & commercial milestone along with royalties on commercial sales
• Genmab obtains an exclusive research right to use Synaffix ADC technologies for one drug target along with an option for development & commercialization globally of ADCs & also gets the option for exclusive license rights in research & commercialization for additional targets
• Genmab will lead the development, manufacturing & commercialization of ADC therapies. Synaffix will support Genmab’s research activities including manufacturing of components related to its ADC technologies

Ref: Globe Newswire | Image: European Biotechnology